Rhythm Biotherapeutics Inc
- Biotech or pharma, therapeutic R&D
Rhythm Biotherapeutics Inc. (RBI) is a preclinical-stage biotechnology company developing a novel exosome therapy to treat atrial fibrillation. Peer-reviewed preclinical studies in animal models demonstrate that this therapy effectively reduces postoperative atrial fibrillation (POAF) incidence by targeting the NLRP3 inflammasome pathway, a key driver of atrial inflammation and fibrosis.
The therapy’s mechanism involves suppressing NLRP3-mediated inflammatory signaling and subsequent fibrotic remodeling, addressing the root physiological causes of atrial fibrillation. This approach builds on research showing NLRP3 inflammasome activation directly contributes to atrial fibrillation by promoting ectopic electrical activity and structural changes in cardiac tissue.
Our lead asset is focused on reducing POAF resulting from cardiac surgery. Pipeline assets focus on broadened indications for improved outcomes from catheter ablation and first onset atrial fibrillation.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}